[18F]AlF-NOTA-FAPI-04 PET/CT预测可切除食管鳞状细胞癌对新辅助卡瑞利珠单抗联合化疗病理反应:一项II期临床试验
这项单中心、单臂II期试验(ChiCTR2100050057)纳入32例新诊断局部晚期食管鳞状细胞癌(LA-ESCC)患者,评估[18F]AlF-NOTA-FAPI-04(18F-FAPI)PET/CT预测新辅助卡瑞利珠单抗联合化疗(nCC)后病理反应的能力;其中23例在2周期nCC后再次扫描,所有患者2周期nCC后接受手术。病理学良好反应组与不良反应组各16例(16/32,50.0%);nCC后SUVmax、SUVpeak、SUVmean、TBRmax、TBRmean及部分SUV变化量可显著预测病理反应。结论:治疗后18F-FAPI PET/CT参数及其相对基线的变化可预测LA-ESCC患者对nCC的病理反应。
要点
- 良好与不良病理反应组各16例(16/32,50.0%)。
- nCC后良好反应组SUV显著低于不良反应组,且SUV变化量显著更高(均P<0.05)。
- nCC后SUVmax、SUVpeak、SUVmean、TBRmax、TBRmean及部分SUV变化量可预测病理反应。
核心结论
- 治疗后18F-FAPI PET/CT参数及其相对基线的变化可预测LA-ESCC患者对nCC的病理反应。
研究设计与样本
- 单中心、单臂II期临床试验(ChiCTR2100050057),纳入32例新诊断LA-ESCC患者。
- 基线时行18F-FAPI PET/CT,其中23例在2周期nCC后再次扫描。
- 所有患者2周期nCC后接受手术,记录SUVmax、SUVpeak、SUVmean、TBR、代谢肿瘤体积和总病灶FAP表达等PET参数。
- 比较病理学良好反应组与不良反应组的PET参数,并分析预测疗效的性能。
主要发现
- 良好反应组与不良反应组各16例(16/32,50.0%)。
- nCC后良好反应组SUV显著低于不良反应组,而SUV随治疗的变化量显著更高(均P<0.05)。
- nCC后SUVmax预测病理反应AUC 0.87(P=0.0026),SUVpeak AUC 0.89(P=0.0017),SUVmean AUC 0.88(P=0.0021),TBRmax AUC 0.86(P=0.0031),TBRmean AUC 0.88(P=0.0021),灵敏度63.64%-81.82%,特异度83.33%-100%。
- SUVmax变化量预测病理反应AUC 0.81(P=0.0116),SUVpeak变化量AUC 0.82(P=0.0097),SUVmean变化量AUC 0.81(P=0.0116),TBRmean变化量AUC 0.74(P=0.0489),灵敏度和特异度在相似范围。
临床怎么用
- 作者认为,治疗后18F-FAPI PET/CT参数及其相对基线的变化可预测LA-ESCC患者对nCC的病理反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This single-center, single-arm, phase II trial (ChiCTR2100050057) investigated the ability of 18F-labeled fibroblast activation protein inhibitor ([18F]AlF-NOTA-FAPI-04, denoted as 18F-FAPI) PET/CT to predict the response to neoadjuvant camrelizumab plus chemotherapy (nCC) in locally advanced esophageal squamous cell carcinoma (LA-ESCC). Methods: This study included 32 newly diagnosed LA-ESCC participants who underwent 18F-FAPI PET/CT at baseline, of whom 23 also underwent scanning after 2 cycles of nCC. The participants underwent surgery after 2 cycles of nCC. Recorded PET parameters included maximum, peak, and mean SUVs and tumor-to-background ratios (TBRs), metabolic tumor volume, and total lesion FAP expression. PET parameters were compared between patient groups with good and poor pathologic responses, and the predictive performance for treatment response was analyzed. Results: The good and poor response groups each included 16 participants (16/32, 50.0%). On 18F-FAPI PET/CT, the posttreatment SUVs were significantly lower in good responders than in poor responders, whereas the changes in SUVs with treatment were significantly higher (all P < 0.05). SUVmax (area under the curve [AUC], 0.87; P = 0.0026), SUVpeak (AUC, 0.89; P = 0.0017), SUVmean (AUC, 0.88; P = 0.0021), TBRmax (AUC, 0.86; P = 0.0031), and TBRmean (AUC, 0.88; P = 0.0021) after nCC were significant predictors of pathologic response to nCC, with sensitivities of 63.64%-81.82% and specificities of 83.33%-100%. Changes in SUVmax (AUC, 0.81; P = 0.0116), SUVpeak (AUC, 0.82; P = 0.0097), SUVmean (AUC, 0.81; P = 0.0116), and TBRmean (AUC, 0.74; P = 0.0489) also were significant predictors of the pathologic response to nCC, with sensitivities and specificities in similar ranges. Conclusion: 18F-FAPI PET/CT parameters after treatment and their changes from baseline can predict the pathologic response to nCC in LA-ESCC participants.
引用
- Dong Y, Wang Z, Hu X, et al. [18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial. J Nucl Med. 2024. PMID: 39327020. doi:10.2967/jnumed.124.268557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。